Captrust Financial Advisors Has $180,000 Position in Certara, Inc. (NASDAQ:CERT)

Captrust Financial Advisors reduced its position in shares of Certara, Inc. (NASDAQ:CERT) by 29.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,370 shares of the company’s stock after selling 6,396 shares during the quarter. Captrust Financial Advisors’ holdings in Certara were worth $180,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Blue Trust Inc. acquired a new position in shares of Certara during the second quarter worth about $26,000. Innealta Capital LLC acquired a new position in shares of Certara during the second quarter worth about $36,000. KBC Group NV boosted its position in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares during the period. Intech Investment Management LLC acquired a new position in Certara during the second quarter valued at approximately $152,000. Finally, Algert Global LLC acquired a new position in Certara during the second quarter valued at approximately $156,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.39% of the stock is owned by corporate insiders.

Certara Stock Performance

CERT opened at $11.57 on Tuesday. Certara, Inc. has a 12-month low of $9.41 and a 12-month high of $19.87. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -57.85, a PEG ratio of 5.86 and a beta of 1.53. The business has a 50 day moving average of $10.85 and a 200-day moving average of $12.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business’s revenue was up 10.7% on a year-over-year basis. During the same period last year, the firm posted $0.06 earnings per share. On average, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CERT shares. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, September 27th. Barclays reduced their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird reduced their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Certara presently has an average rating of “Hold” and a consensus price target of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.